Last reviewed · How we verify

Pre-Quit Nicotine Patch

University of Wisconsin, Madison · FDA-approved active Small molecule

Delivers nicotine transdermally to reduce withdrawal symptoms and cravings during smoking cessation.

Delivers nicotine transdermally to reduce withdrawal symptoms and cravings during smoking cessation. Used for Smoking cessation aid.

At a glance

Generic namePre-Quit Nicotine Patch
SponsorUniversity of Wisconsin, Madison
Drug classNicotine replacement therapy (NRT)
TargetNicotinic acetylcholine receptors
ModalitySmall molecule
Therapeutic areaSmoking Cessation / Addiction Medicine
PhaseFDA-approved

Mechanism of action

The patch provides a steady, controlled release of nicotine through the skin, bypassing the rapid peaks and valleys of cigarette smoking. This maintains adequate nicotine levels to suppress withdrawal symptoms and reduce the reinforcing effects of smoking, allowing users to gradually taper nicotine doses. The transdermal route avoids the addictive delivery kinetics of inhaled nicotine while supporting behavioral cessation efforts.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: